BioMedNewsBreaks

MondayDec 14, 2020 10:53 am

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Strategic Board Appointment

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological protection for high value crops, today announced the appointment of David M. Borecky, vice president and chief accounting officer of Impossible Foods, to its board of directors. According to the update, David will leverage his extensive global relationships in the plant-based innovation community to accelerate and raise awareness of MustGrow's remarkably safe and effective plant-based crop protection technologies. "David's strong connections within the Silicon Valley and plant-based culture communities will prove instrumental in our development of plant-based biopesticides for a sustainable food supply," said…

Continue Reading

FridayDec 11, 2020 2:45 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Engages Dalmore Group for Expert Strategic Advice, Innovative Solutions

Brain Scientific (OTCQB: BRSF), a commercial-stage health-care company focused on developing innovative and proprietary medical devices and software, recently entered into a strategic partnership with the Dalmore Group. A member of FINRA and SIPC, the Dalmore Group maintains an active presence in the Regulation A+ equity funding space. The company is one of the world’s most active broker-dealers and has served on more than 50 RegA+ offerings in the past 12 months, raising more than $1 billion of capital in 2019. The Dalmore Group secures the majority of its clients by referral from securities attorneys and industry participants. A recent…

Continue Reading

FridayDec 11, 2020 2:35 pm

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Advancing MS1819 in Fight to Improve Treatment of EPI in CF, CP Patients

AzurRx BioPharma (NASDAQ: AZRX) is focused on the development of its lead drug candidate, MS1819, for exocrine pancreatic insufficiency (“EPI”) in patients suffering from cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). While CF is a relatively rare genetic disease, innovative and effective therapies are needed. CF is a dangerous condition that affects multiple body functions and organs, putting patients at risk of developing severe life-threatening illnesses. Technological advances have greatly increased the life span for CF patients. While children with CF rarely made it to elementary school age in the 1950s, the median age of survival for a CF patient…

Continue Reading

FridayDec 11, 2020 1:39 pm

BioMedNewsBreaks – GC Pharma’s Promising Research, Shincheonji Church Plasma Drive Offer Ray of Hope for Latin American COVID-19 Patients

GC Pharma and Shincheonji Church are offering assistance for the Latin American countries ravaged by the COVID-19 pandemic. A recent breakthrough in GC Pharma’s COVID-19 research was achieved on Dec. 6, 2020, when a COVID-19 patient recovered after receiving GC Pharma’s blood plasma therapy. The therapy, GC5131, was developed by fractioning an antibody with the immunogenicity from the plasma of a recovered COVID-19 patient. Many Latin American hospitals already use GC Pharma’s IVIG-SN treatment to save patients from various illnesses, and this breakthrough may also open doors for GC Pharma’s blood plasma therapy to be administered to Latin American COVID-19…

Continue Reading

ThursdayDec 10, 2020 10:41 am

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Granted Patent for Innovative Treatment for MDD

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has been granted a patent by the Korean Intellectual Property Office (“KIPO”) for one of its treatments for depression. VistaGen received notification that KIPO has issued a decision to grant Patent Application No. 10-2015-7020176. The patent relates to VistaGen's PH10, an investigational neuroactive nasal spray designed to have rapid-onset therapeutic potential in a variety of neuropsychiatric indications involving depression; the patent will not expire earlier than 2034. VistaGen is…

Continue Reading

ThursdayDec 10, 2020 9:48 am

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by the Benchmark Company LLC. The report, titled “Processa Pharmaceuticals Inc. (PCSA) Processing Assets to the FDA; Initiate at Buy,” lists a $15 price target at initiation of coverage. The report reads, “We initiate PCSA with a Speculative Buy rating as we consider the two leading assets in PCSA’s pipeline portfolio as most promising and with potential value. Eniluracil probably can reduce adverse events and improve efficacy of 5-FU/capecitabine…

Continue Reading

WednesdayDec 09, 2020 1:40 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Issues Shareholder Letter Regarding Special Meeting

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today sent a letter to shareholders regarding its virtual special meeting of stockholders, originally scheduled for Dec. 1, 2020, which will be reconvened to 3 p.m. CST on Dec. 30, 2020. According to the update, POAI’s board of directors and management urge all shareholders to vote in favor of the proposals being considered at the special meeting, primarily because the reincorporation in Nevada will eliminate its obligation to pay the injurious annual Delaware franchise tax, currently equal to approximately $170,000 per…

Continue Reading

WednesdayDec 09, 2020 1:00 pm

BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) to Participate at LD Micro Main Event

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced that Dr. Jack Regan, LexaGene’s CEO and founder, will present at the 13th Annual LD Micro Main Event Conference. Interested parties should visit https://ibn.fm/tKpNj to register for the event, slated to be held on Dec. 15, 2020. In addition, the company announced that it has engaged Native Ads Inc. of New York to perform strategic digital media, marketing and data analytics services including, but not limited to, content development, video production and editing, website development, media buying and distribution, and campaign…

Continue Reading

WednesdayDec 09, 2020 11:46 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Describes ‘Most Exciting Thing That I’ve Done’ on Gamechangers LIVE

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently appeared on Gamechangers LIVE, a podcast series that shines a spotlight on gamechangers in various industries, sharing perspective on journeys, mindsets, struggles and successes in an effort to inspire and inform listeners. During the interview, CNSP’s chairman and CEO, John Climaco, provided an overview of CNS Pharmaceuticals and its lead drug candidate, Berubicin. Proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer, Berubicin was evaluated in…

Continue Reading

WednesdayDec 09, 2020 10:49 am

BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) Announces Live Investor Webcast; Provides Overview of Biopesticide Pipeline

MustGrow (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) has provided an update of its natural plant-based, mustard-derived biopesticide technology product pipeline. The company is intent on using the natural defense mechanism of the mustard seed to develop and commercialize biopesticide technologies; MustGrow is using the technology to control diseases, pests and weeds. The company is planning a live investor webcast today to discuss upcoming catalysts; the webcast is slated to begin at 11 a.m. ET. Anyone interested in attending should sign in five minutes early. Participants will be anonymous and muted, but questions can be sent to the company (info@mustgrow.ca) before…

Continue Reading